At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 251 enrolled
Drug / intervention
Delgocitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose Ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Applications of Delgocitinib Cream 1, 3, 8, 20 mg/g for 8 Weeks in Adult Subjects With Mild to Severe Atopic Dermatitis.
In Brief
A Phase 2 clinical trial evaluating Delgocitinib cream and Delgocitinib cream vehicle for Atopic Dermatitis. Completed, enrolled 251 participants across 31 sites in 3 countries.
Detailed Summary
This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the treatment of adult subjects with mild to severe atopic dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Canada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartDec 2018
Primary CompletionMay 2020
TodayJul 2026
First PostedOct 31, 2018
Enrollment StartDec 28, 2018
Primary CompletionMay 19, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.7 years ago
Interventions
Delgocitinib creamdrug
Cream for topical application
Delgocitinib cream vehicledrug
The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.